Posoleucel

泊索仑赛

Report date: 2025/04/23 20:01:04

Base Information

Drug NamePosoleucel

Drug Alias NameMultivirus-specific T cell therapyViralym-MALVR-105

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derived

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsBK Polyomavirus InfectionsCystitisPolyomavirus Infections +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumCanadaUnited States +[11]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesBaylor College Of Medicine

China Registration ClassN/A

Develop Information

Active CompaniesKalaris Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsBK Polyomavirus InfectionsPolyomavirus InfectionsEpstein-Barr Virus Infections +[5]

Inactive IndicationsCystitis

Other Information

ATC CodeN/A